Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishikawa, S.
Right arrow Articles by Tanaka, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishikawa, S.
Right arrow Articles by Tanaka, F.
Clinical Cancer Research Vol. 10, 6579-6585, October 1, 2004
© 2004 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non–Small-Cell Lung Cancer

Shinya Ishikawa1,2, Kazumasa Takenaka1, Kazuhiro Yanagihara1,3, Ryo Miyahara1, Yozo Kawano1, Yosuke Otake4, Seiki Hasegawa1, Hiromi Wada1 and Fumihiro Tanaka1

1 Department of Thoracic Surgery, Kyoto University, Faculty of Medicine, Kyoto; 2 Second Department of Surgery, Faculty of Medicine, Kagawa University, Kita-gun; 3 Department of Translational Clinical Oncology, Graduate School of Medicine, Kyoto University, Kyoto; and 4 Department of Thoracic Surgery, Seishin-Iryo Center Hospital, Kobe, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: The purpose is to assess clinical significance of matrix metalloproteinase (MMP)-2 and MMP-9 status, especially MMP-2 status, in stromal cells in non–small-cell lung cancer (NSCLC) because experimental studies have revealed that stromal MMP-2 plays important roles in progression of malignant tumors, but most clinical studies focused on tumoral MMP-2 expression, not stromal MMP-2 expression.

Experimental Design: We conducted a retrospective study on MMP-2 and MMP-9 expression as evaluated immunohistochemically in a total of 218 consecutive patients with completely resected pathological stage I–IIIA, NSCLC.

Results: Strong MMP-2 expression in tumor cells and stromal fibroblasts were documented in 54 (24.8%) and 132 (60.6%) patients, respectively. Strong MMP-2 expression in stromal fibroblasts was more frequently seen in squamous cell carcinoma (72.7%) than in adenocarcinoma (54.9%; P = 0.016). Tumors showing strong MMP-2 expression in stromal fibroblasts showed a significantly higher intratumoral microvessel density (IMVD) than weak stromal MMP-2 tumors (mean intratumoral microvessel density, 50.9 versus 32.4, P = 0.003). In addition, postoperative prognosis of strong stromal MMP-2 patients was significantly poorer than that of weak stromal MMP-2 patients (5-year survival rate, 77.5 versus 60.2%, P = 0.032), and the prognostic significance was enhanced in squamous cell carcinoma patients but disappeared in adenocarcinoma patients. Multivariate analyses confirmed that strong stromal MMP-2 expression was a significant factor to predict a poor prognosis in squamous cell carcinoma patients, not in adenocarcinoma patients. In contrast, MMP-2 or MMP-9 status in tumor cells was not a significant prognostic factor.

Conclusions: MMP-2 status in stromal fibroblasts, not in tumor cells, was a significant prognostic factor associated with angiogenesis in NSCLC.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Primary lung cancer is the most common cause of cancer-related deaths in most industrialized countries, and non–small-cell lung cancers (NSCLCs) account for ~80% of primary lung cancer (1) . Therefore, it is necessary to establish clinical markers, other than the tumor-node-metastasis staging system, that may predict the prognosis and response toward a specific therapy. Although experimental studies have revealed many biological markers that may be correlated with development and progression of malignant tumors, including NSCLC, no biological markers have been established as a clinical marker in the diagnosis or therapy (2) .

Recent experimental studies have revealed that degradation of the extracellular matrix (ECM) by matrix metalloproteinases (MMPs) is a critical process in progression of malignant tumors, including NSCLC, because degradation of the ECM is required in tumor angiogenesis, as well as tumor invasion and metastases (3, 4, 5, 6, 7) . Among many MMPs that have been identified, MMP-2 (Gelatinase-A) and MMP-9 (Gelatinase-B) are thought to be key enzymes as they degrade type IV collagen, the main component of ECM (6 , 7) . After these experimental studies, many clinical studies on MMP-2 and/or MMP-9 expression in malignant tumors, including NSCLC, have been conducted (8, 9, 10, 11, 12, 13) , but the clinical significance remains controversial (6) . In addition, in most clinical studies, MMP expression only in tumor cells was assessed, whereas experimental studies have revealed that stromal tumor cells as well as tumor cells do express MMPs, especially MMP-2, and stromal fibroblast expression MMP-2 plays an important role in tumor progression (6 , 14) . Thus, we conducted a large-scale clinical study on MMP-2 and MMP-9 expression in tumor cells and in stromal fibroblasts as evaluated immunohistochemically to clarify the clinical significance in resected NSCLC.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients and Tissue Preparation.
A total of 237 consecutive patients with pathological stage I–IIIA NSCLC, who underwent complete resection without any preoperative therapy at Kyoto University Hospital from January 1, 1985, through December 31, 1990, was retrospectively reviewed. One patient was excluded from the study due to operation-related death, and 18 patients in evaluation of MMP-2 and 23 patients in evaluation of MMP-9 were excluded from the study due to lack of surgical specimens, and finally a total of 218 patients in evaluation of MMP-2 and 213 patients in evaluation of MMP-9 was evaluated (Table 1Citation ; refs. 15, 16, 17 ). p-stage and histologic type were reevaluated and determined with the current tumor-node-metastasis classification as revised in 1997 (18) and the current classification by WHO as revised in 1999 (19) , respectively.


View this table:
[in this window]
[in a new window]

  		Table 1 Expression of MMP-2 in stromal fibroblasts and tumor cells in non-small cell lung cancer

 
For all these patients, the inpatient medical records, chest X-ray films, whole-body computed tomography films, bone scanning data, and records of surgery were reviewed. Intraoperative therapy was not performed in any patient. As postoperative adjuvant therapy, cisplatin-based chemotherapy, radiation, and oral administration of tegafur (a fluorouracil-derivative drug) were prescribed for 55, 35, and 58 patients, respectively (15) . Follow-up of the postoperative clinical course was conducted by outpatient medical records and by inquiries by telephone or letter.

All primary tumor specimens were immediately fixed in 10% (v/v) formalin and then embedded in paraffin. Serial 4-µm sections were prepared from each sample and served for H&E staining, immunohistochemical staining, and the terminal deoxynucleotidyltransferase-mediated nick end labeling staining. Results of immunohistochemical staining and terminal deoxynucleotidyltransferase-mediated nick end labeling staining were evaluated by two authors independently (S. Ishikawa and F. Tanaka) without knowledge of any clinical data. In case of a discordant evaluation after reevaluation, the slides were evaluated by another author (K. Takenaka). This study has been approved by the Ethics Committee, Graduate School and Faculty of Medicine, Kyoto University.

Evaluation of MMP-2 and MMP-9 Expression.
Expression of MMP-2 and MMP-9 was assessed immunohistochemically using a standard streptavidin-biotinylated horseradish peroxidase complex method (LSAB+ kit/HRP; Dako, Kyoto, Japan). For antigen retrieval, sections were autoclaved at 121°C for 5 minutes in 0.01 mol/L citrate buffer (pH 6.0), and then sections were incubated in methanol containing 0.03% H2O2 (Nakalai Tesque, Kyoto, Japan) for 30 minutes. After incubation in a nonspecific staining blocking agent (BlockAce; Dainihon Seiyaku, Osaka, Japan), sections were incubated overnight at 4°C with each primary antibody as follows: an antihuman MMP-2 monoclonal antibody (mAb) (500 µg/mL mouse IgG1/{kappa}, F-68; Daiichi Fine Chemical Co. Ltd., Tokyo, Japan) diluted at 1/200 and an antihuman MMP-9 monoclonal antibody (500 µg/mL mouse IgG1/{kappa}, F-69; Daiichi Fine Chemical Co. Ltd.) diluted at 1/250. As a negative control, each section was treated without the primary antibody.

MMP-2 or MMP-9 expression in tumor cells and MMP-2 expression in stromal fibroblasts were classified according to the following grading system. MMP-9 expression in stromal cells was not assessed because the expression was negative or faint. A percentage score was defined as follows: score 0 if the percentage positive staining cells was ≤25%, score 1 if the percentage was >25 and ≤50%, and score 2 if the percentage was >50%; an intensity score was defined as follows: score 0 if no staining was documented, score 1 if the staining intensity was weak, score 2 if the intensity was moderate, and score 3 if the intensity was high. Each section was finally classified based on the sum of the percentage score and the intensity score as follows: weak expression when the sum was ≤3 and strong expression when the sum was 4 or 5.

Expression of vascular endothelial growth factor (VEGF) was also evaluated immunohistochemically as described previously (16 , 17) . Briefly, an anti-VEGF polyclonal antibody A-20 (200 µg/mL rabbit IgG; Santa Cruz Biotechnology, Santa Cruz, CA) diluted at 1/50 was used as the primary antibody. VEGF expression was also evaluated according to the same scoring system and was finally classified into weak or strong expression based on the score (16 , 17) .

Quantification of Angiogenesis [Intratumoral Microvessel Density (IMVD)].
IMVD, a measurement of tumor angiogenesis, was evaluated immunohistochemically as described in previous studies (16 , 17) . Briefly, immunohistochemical staining for CD34 (a pan-endothelial marker) and CD 105 (a proliferation-related endothelial marker) to highlight endothelial cells was performed using a sensitive streptavidin-biotinylated horseradish peroxidase complex system (TSA-Indirect kit; NEN Life Science Products, Boston, MA). Primary antibodies used were an anti-CD34 mAb QBEnd10 (50 µg/mL mouse IgG1/{kappa}; Dako), diluted at 1/50, and an anti-CD105 mAb SN6 h (366 µg/mL mouse IgG1/{kappa}; Dako), diluted at 1/100. The 10 most vascular areas within a section were selected for evaluation of angiogenesis, and vessels labeled with the anti-CD34 mAb or the anti-CD105 mAb were counted under light microscopy with a 200-fold magnification. The average counts were recorded as theCD34-IMVD or CD105-IMVD for each case.

Evaluation of Cell Proliferation, Apoptotic Cell Death, and p53 Status.
Proliferative activity of tumor cells was evaluated by immunohistochemical staining using a mAb against proliferative cell nuclear antigen (clone PC-10, 400 µg/mL mouse IgG2a/{kappa}; Dako) as described previously (15) . A total of 1000 tumor cells was counted for positive staining, and the proliferative activity was represented as the percentage of proliferative cell nuclear antigen-positive tumors cells.

The terminal deoxynucleotidyltransferase-mediated nick end labeling staining to detect apoptotic cells was performed using In Situ Death Detection kit POD (Boehringer Mannheim, Mannheim, Germany) as described previously (15) . In each case, a total of 10,000 tumor cells was evaluated, and apoptotic index was defined as the number of apoptotic cells per 1000 tumor cells.

Evaluation of p53 status was performed by immunohistochemical staining using an antihuman p53 mAb DO-7 (250 µg/mL mouse IgG2b/{kappa}; Dako) diluted at 1:50 as described previously (15) . When the percentages of positive cells exceed 5%, each section was judged to exhibit aberrant p53 expression.

Statistical Methods.
The {chi}2 was used to compare counts. Continuous data were compared using Student’s t test, if the distribution of samples was normal, or the Mann-Whitney U test, if the sample distribution was asymmetrical. Postoperative survival was analyzed by the Kaplan-Meier method, and the difference was assessed by the log-rank test. A multivariate analysis of prognostic factors was performed using a Cox’s regression model. Differences were considered significant when P < 0.05. All statistical manipulations were performed using the SPSS for Windows software system (SPSS, Inc., Chicago, IL).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of MMP-2 and MMP-9 in NSCLC.
Expression of MMP-2 and MMP-9 was seen mainly in the cytoplasm of tumor cells (Fig. 1)Citation , and strong MMP-2 and MMP-9 expression in tumor cells were seen in 54 (24.8%) and 98 (46.0%) patients, respectively (Table 1)Citation . Strong MMP-2 expression in tumor cells was more frequent in adenocarcinoma patients (38 of 122, 31.1%) than in squamous cell carcinoma patients (10 of 77, 13.0%, P = 0.004), and the mean age of patients with strong tumoral MMP-2 expression was significantly lower than that of patients with weak tumoral MMP-2 expression (59.5 and 63.5years, respectively, P = 0.006; Table 1Citation ). There was no significant correlation between tumoral MMP-9 status and any patient characteristic (data not shown).



View larger version (115K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. MMP-2 expression in NSCLC with immunohistochemical staining. A. Positive MMP-2 staining was seen in stromal fibroblasts in a squamous cell carcinoma patient; MMP-2 expression was negative in tumor cells. B. Positive MMP-2 staining was seen in tumor cells in an adenocarcinoma carcinoma patient; MMP-2 expression was negative in stromal fibroblasts. C. Positive MMP-9 staining was seen in tumor cells in a large cell carcinoma patient.

 
Strong MMP-2 expression in the stromal fibroblasts was also seen in 132 (60.6%) of all patients (Fig. 1Citation and Table 1Citation ), whereas no definite MMP-9 expression was seen in any patient. In contrast to tumoral MMP-2 expression, strong MMP-2 expression in stromal fibroblasts was more frequent in squamous cell carcinoma patients (56 of 77, 72.7%) than in adenocarcinoma patients (67 of 122, 54.9%, P = 0.016; Table 1Citation ). No significant correlation between stromal MMP-2 status and other patient characteristics was documented (Table 1)Citation .

MMP-2 Status and Other Biomarkers.
The mean VEGF score for strong tumoral MMP-2 tumor (4.15) was significantly higher than that for weak tumoral MMP-2 tumor (3.58, P = 0.030). No significant difference in the mean VEGF score according to the stromal MMP-2 status (Table 2)Citation .


View this table:
[in this window]
[in a new window]

  		Table 2 Biomarkers according to expression of MMP-2

 
The mean CD105-IMVD for strong stromal MMP-2 tumor (50.9) was significantly higher than that for weak stromal MMP-2 tumor (32.4. P = 0.003), whereas no significant difference in the mean CD34-IMVD was documented (Table 2)Citation . The difference in the mean CD105 according to the stromal MMP-2 status was marked in squamous cell carcinoma (P = 0.002; Fig. 2ACitation ) and was not significant in adenocarcinoma (P = 0.491; Fig. 2BCitation ). When combined with VEGF status in tumor cells, the effect of stromal MMP-2 status on CD105-IMVD was enhanced (Fig. 3)Citation ; tumor with strong tumoral VEGF expression and strong stromal MMP-2 expression showed the highest CD105-IMVD, and tumor with weak tumoral VEGF expression and weak stromal MMP-2 expression showed the lowest CD105-IMVD. There was no difference in the mean CD105-IMVD or CD34-IMVD according to the tumoral MMP-9 status (data not shown).



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. A. IMVD in squamous cell carcinoma according to the status of MMP-2 expression in stromal fibroblasts and MMP-2 expression in tumor cells. IMVD was determined with an anti-CD105 antibody. (Each column shows the mean IMVD value, and the error bars show the SE.) B. IMVD in adenocarcinoma according the status of MMP-2 expression in stromal fibroblasts and MMP-2 expression in tumor cells. IMVD was determined with an anti-CD105 antibody. (Each column shows the mean IMVD value, and the error bars show the SE.)

 


View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. IMVD in NSCLC according to the status of MMP-2 expression in stromal fibroblasts in combination with the status of VEGF expression in tumor cells. IMVD was determined with an anti-CD105 antibody (CD105-IMVD; left) or with an anti-CD34 antibody (CD34-IMVD; right).

 
Strong stromal MMP-2 tumor showed a significantly higher proliferative index (50.6) than weak stromal MMP-2 tumor (39.3, P = 0.004; Table 2Citation ). There was no significant difference in other biomarker according to the stromal MMP-2 status (Table 2)Citation .

MMP-2 and MMP-9 Status and Postoperative Survival.
Five-year survival rates of the patients with weak MMP-2 expression and strong MMP-2 expression in stromal fibroblasts were 77.5 and 60.2%, showing that weak stromal MMP-2 patients showed a significantly favorable postoperative survival (P = 0.032; Table 3Citation and Fig. 4Citation ). Subset analyses revealed that the prognostic significance of MMP-2 status in stromal fibroblasts was evident in squamous cell carcinoma patients, especially pathological stage I squamous cell carcinoma patients, but disappeared in adenocarcinoma patients (Table 3)Citation . Multivariate analyses showed that MMP-2 status in stromal fibroblasts was a marginal prognostic predictor for all NSCLC patients [P = 0.064; relative hazard, 1.666, 95% confidence interval (0.971–2.856)]; stromal MMP-2 status was an independent and significant prognostic predictor for squamous cell carcinoma patients (P = 0.022; relative hazard, 9.828, 95% confidence interval (1.414–22.911)] but not for adenocarcinoma patients (P = 0.745; relative hazard, 1.119, 95% confidence interval (0.568–2.206)].


View this table:
[in this window]
[in a new window]

  		Table 3 Postoperative survival according to expression of MMP-2

 


View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Postoperative survival of completely resected pathological stage I–IIIA, NSCLC. Comparison according to the status of MMP-2 expression in stromal fibroblasts. Weak MMP-2 expression in stromal fibroblasts 5-year survival: 77.5%. Strong MMP-2 expression in stromal fibroblasts 5-year survival: 60.2%.

 
There was no significant difference in the postoperative survival according to MMP-2 status or MMP-9 status in tumor cells. (Tables 3Citation and 4Citation ).


View this table:
[in this window]
[in a new window]

  		Table 4 Multivariate analysis of prognostic factors in NSCLC

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we revealed that MMP-2 status in stromal fibroblasts was a significant prognostic factor in NSCLC, especially in squamous cell carcinoma, which was the first study that documented the clinical importance of MMP status in stromal cells, not in tumor cells. Although it had been initially believed that MMPs derived from tumor cells played principal roles in tumor progression, recent experimental studies have revealed that stromal cells also express MMPs, especially MMP-2, and that MMPs derived from stromal cells play equally or more important roles (6) . Despite these experimental results, no clinical studies have focused on MMP expression in stromal cells; in a few studies assessing stromal MMP-2 expression, little has been reported on correlation between stromal MMP-2 status and clinicopathological features (20, 21, 22) . In a clinical study on MMPs in squamous cell carcinoma of the lung, weak MMP-2 expression in tumor cells and enhanced MMP-2 expression in stromal fibroblasts were documented (21) , which was in accordance with the results documented in the present study. In contrast to MMP-2, MMP-9 expression in stromal fibroblasts was negative in most patients and faint in some cases, which was same as results documented in other studies (20 , 21) . These results strongly suggested that MMP-2, not MMP-9, derived from stromal fibroblasts might play critical roles in tumor progression of NSCLC, especially squamous cell carcinoma. Most postoperative recurrence occurred not as local recurrence but as distant recurrence, and a difference in the metastatic sites according to the status of MMP-2 expression should be investigated in future studies.

In contrast to stromal MMP-2 status, MMP-2 or MMP-9 status in tumor cells did not provide a prognostic significance in the present study, although many clinical studies showed that enhanced MMP-2 and/or MMP-9 expression in tumor cells was a significant factor to predict a poor prognosis (8, 9, 10, 11, 12, 13) . In some clinical studies, it has been reported that enhanced expression of MMPs such as MMP-9 may be associated with reduced metastatic proclivity and favorable prognosis (6 , 23 , 24) . These discrepancies may suggest limits of such retrospective studies. Thus, to assess and establish the prognostic significance of MMP-2 and MMP-9 status in tumor cells, as well as MMP-2 status in stromal fibroblasts, prospective clinical studies should be conducted. In addition, recent experimental studies have revealed that proteolytic degradation of ECM barriers by MMPs and other proteolytic enzymes is not essential for tumor cell migration and/or invasion (25) . These results suggest that tumor progression and prognosis may not be predicted by the status of MMPs expression.

Many experimental studies have revealed that MMPs, especially MMP-2 and MMP-9, play important roles in tumor angiogenesis because MMPs degrade the ECM and provide a microenvironment for the development of new vessels (3, 4, 5, 6) , but only a few clinical studies documented correlations between MMPs expression and tumor angiogenesis where enhanced expression of MMP-9, not MMP-2, in tumor cells was correlated with elevated IMVD (26, 27, 28) . We documented a significantly higher CD105-IMVD in tumor with strong MMP-2 expression in stromal fibroblasts, and no significant difference in IMVD according to tumoral MMP-2 or MMP-9 status in the present study. CD 105 (endoglin) is a Mr 180,000 homodimetric membrane glycoprotein expressed on endothelial cells that can bind transforming growth factor ß1 and transforming growth factor ß3, and experimental studies have revealed that CD105 is a marker of proliferating endothelial cells; anti-CD 105 antibodies have greater affinity for activated endothelial cells and preferentially bind to activated endothelial cells in tissues participating in angiogenesis (29) . Thus, in contrast to antibodies against pan-endothelial cells such as anti-CD34 antibodies, anti-CD105 antibodies preferentially react with endothelial cells of all angiogenic tissues, including tumors, but weakly or not at all with those of most normal tissues. In clinical studies, we reported that increased CD105-IMVD, not CD34-IMVD, was significantly correlated with poor postoperative survival, as well as lower incidence of apoptotic cell death in NSCLC (16 , 30) , which was consistent with the results in breast cancer reported by Kumar et al. (31) . The validity of use of CD105 a marker of angiogenesis along with the correlation between MMPs status and angiogenesis should be in future prospective.

In conclusion, enhanced MMP-2 expression in stromal cells, not in tumor cells, was a significant factor to predict a poor postoperative survival in NSCLC, especially squamous cell carcinoma, which might be correlated with active tumor angiogenesis. These results added a new insight into tumor angiogenesis and clinical outcomes in NSCLC and warrant a prospective study to confirm the clinical significance of MMPs status in stromal cells.


   FOOTNOTES
 
Grant support: Grants-in-Aid 14370410 (F. Tanaka) for Scientific Research (B) and 15390411 (S. Hasegawa) for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. This work was also supported by a grant from The Japanese Foundation for Multidisciplinary Treatment of Cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Fumihiro Tanaka, Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan. Phone: 81-75-751-4975; Fax: 81-75-751-4974; E-mail: ftanaka{at}kuhp.kyoto-u.ac.jp

Received 2/12/04; revised 4/19/04; accepted 4/28/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Shottenfeld D. Epidemiology of lung cancer PASS HI Mitchell JB Johnson DH Turrisi AT Minna JD eds. . Lung cancer 2000367-88. Lippincott Williams & Wilkins Philadelphia
  2. Pfister DG, Johnson DH, Azzoli CG, et al American Society of Clinical Oncology. Treatment of unresectable non–small-cell lung cancer guideline. J Clin Oncol update 2003;22:1-24.
  3. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis (Lond.) 2000;21:505-15.[Abstract/Free Full Text]
  4. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-72.[Abstract]
  5. Fortunato SJ, Menon R. Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. J Assisted Reprod Genet 2002;19:483-6.[CrossRef][Medline]
  6. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.[CrossRef][Medline]
  7. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-21.[CrossRef][Medline]
  8. Passlick B, Sienel W, Seen-Hibler R, et al Overexpression of matrix metalloproteinase 2 predict unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-8.[Abstract/Free Full Text]
  9. Kumaki F, Matsui K, Kawai T, et al Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchiloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001;159:2125-35.[Abstract/Free Full Text]
  10. Cox G, Jones JL, O’Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.[Abstract/Free Full Text]
  11. Herbst RS, Yano S, Kuniyasu H, et al Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6:790-7.[Abstract/Free Full Text]
  12. Shou Y, Hirano T, Gong Y, et al Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non–small-cell lung cancer. Br J Cancer 2001;85:1706-12.[CrossRef][Medline]
  13. Sienel W, Hellers J, Morresi-Hauf A, et al Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003;103:647-51.[CrossRef][Medline]
  14. Liao J, Wolfman JC, Wolfman A. K-Ras regulates the steady-state expression of matrix-metalloproteinase 2 in fibroblasts. J Biol Chem 2003;278:31871-8.[Abstract/Free Full Text]
  15. Tanaka F, Kawano Y, Li M, et al Prognostic significance of apoptotic index in completely resected non-small cell lung cancer. J Clin Oncol 1999;17:2728-36.[Abstract/Free Full Text]
  16. Tanaka F, Otake Y, Yanagihara K, et al Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-5.[Abstract/Free Full Text]
  17. Tanaka F, Ishikawa S, Yanagihara K, et al Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124-9.[Abstract/Free Full Text]
  18. Mountain CF. Revisions in the international system for lung cancer. Chest 1997;111:1710-7.[Abstract/Free Full Text]
  19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors Travis WD eds. . World Health Organization international histological classification of tumors. Histological typing of lung and pleural tumors 3rd ed. 199921-66. Springer Berlin
  20. Nawrocki B, Polette M, Marchand V, et al Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 1997;7:556-64.
  21. Schutz A, Schneudenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C. Diggerential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumor Biol 2002;23:179-84.
  22. Yamamura T, Nakanishim K, Hiroi S, et al Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 2002;35:249-55.[CrossRef][Medline]
  23. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997;88:72-81.[Medline]
  24. Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer (Phila.) 2001;91:1277-83.
  25. Wolf K, Mazo I, Leung H, et al Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;20:267-77.
  26. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep 1998;5:673-7.[Medline]
  27. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenases with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17:1099-105.[Medline]
  28. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002;95:1902-10.[CrossRef][Medline]
  29. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984-92.[Abstract/Free Full Text]
  30. Tanaka F, Otake Y, Yanagihara K, et al Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer 2003;39:289-96.[Medline]
  31. Kumar S, Ghellal A, Li C, et al Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-61.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S.-K. Hwang, H.-T. Lim, A. Minai-Tehrani, E.-S. Lee, J. Park, S. B. Park, G. R. Beck Jr., and M.-H. Cho
Repeated Aerosol Delivery of Carboxyl-terminal Modulator Protein Suppresses Tumor in the Lungs of K-rasLA1 Mice
Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1131 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
B. Bartling, M. Desole, S. Rohrbach, R.-E. Silber, and A. Simm
Age-associated changes of extracellular matrix collagen impair lung cancer cell migration
FASEB J, May 1, 2009; 23(5): 1510 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
G. A. Alyahya, M. Kolko, J. U. Prause, B. S. Nielsen, J. Wang, and S. Heegaard
Matrix Metalloproteinase-2 Is Expressed in Melanoma-Associated Spongiform Scleropathy
Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2806 - 2811.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. P. Cosgrove and R. M. du Bois
Matrix Metalloproteinase-7 Expression in Fibrosing Lung Disease: Restoring the Balance
Chest, May 1, 2008; 133(5): 1058 - 1060.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Ueda, M. Jinbo, T.-S. Li, T. Yagi, K. Suga, and K. Hamano
Computed Tomography-Diagnosed Emphysema, Not Airway Obstruction, Is Associated with the Prognostic Outcome of Early-Stage Lung Cancer.
Clin. Cancer Res., November 15, 2006; 12(22): 6730 - 6736.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Xu, A. L. Mora, J. LaVoy, K. L. Brigham, and M. Rojas
Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L658 - L667.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C-Q Zhu, W Shih, C-H Ling, and M-S Tsao
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.
J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. H. Byun, M. A. Lee, S. Y. Roh, B. Y. Shim, S. H. Hong, Y. H. Ko, S. J. Ko, I. S. Woo, J. H. Kang, Y. S. Hong, et al.
Association between Cyclooxygenase-2 and Matrix Metalloproteinase-2 Expression in Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2006; 36(5): 263 - 268.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishikawa, S.
Right arrow Articles by Tanaka, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishikawa, S.
Right arrow Articles by Tanaka, F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online